ArticleOncology reports2020
Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for non‑small cell lung cancer.
Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Updates on the role of miR-193b in the pathogenesis of human cancers and other diseases.Biochemistry and biophysics reports · 2026Review
- Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors.Frontiers in endocrinology · 2024Article
- The Profiling of Apoptosis-Associated MicroRNA Expressions of the Lung Adenocarcinoma.Thoracic research and practice · 2023Article
- Article
- LINC00174 Suppresses Non-Small Cell Lung Cancer Progression by Up-Regulating LATS2 via Sponging miR-31-5p.Cell journal · 2022Article
- Article
- Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer.Bioinformatics and biology insights · 2022Article
- Hallmarks of exosomes.Future science OA · 2022Review
- Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19.Frontiers in pharmacology · 2022Article
- Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma.Computational and structural biotechnology journal · 2022Article
- Circulating microRNAs as molecular biomarkers for lung adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2022Article
- Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.Cancer medicine · 2021Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- Role of Exosomal Non-coding RNAs in Gastric Cancer: Biological Functions and Potential Clinical Applications.Frontiers in oncology · 2021Review
- Halofuginone inhibits tumorigenic progression of 5-FU-resistant human colorectal cancer HCT-15/FU cells by targeting miR-132-3pOncology letters · 2020Article
- Optical Biosensors for the Detection of Rheumatoid Arthritis (RA) Biomarkers: A Comprehensive Review.Sensors (Basel, Switzerland) · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to explore specific molecular targets for the diagnosis and treatment of non‑small cell lung cancer (NSCLC). The expression profiles of microRNAs (miRNAs) and mRNAs were downloaded from the GEO (GSE102286 and GSE101929) and TCGA databases. After data preprocessing, differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) in cancer and normal tissues were selected and used to construct a DEM‑DEG regulatory network and a protein‑protein interaction (PPI) network. The genes and miRNAs in these networks were subjected to functional enrichment and survival analyses. Several key DEMs and DEGs were verified using RT‑qPCR, and the results were statistically interpreted using a multivariate logistic regression analysis. In this study, 25 DEMs and 789 DEGs common to all datasets were identified, which were then used for the construction of a DEM‑DEG regulatory network and a PPI network module. Survival analyses of 19 DEMs in the DEM‑DEG regulatory network and 36 DEGs in the PPI network module revealed that 34 DEGs (including TOP2A, CCNB1, BIRC5, and TTK) and two miRNAs (miR‑21‑5p and miR‑31‑5p) were significantly associated with NSCLC prognosis. Moreover, RT‑qPCR analysis identified three DEGs and five DEMs that had changes in expression consistent with those observed in the bioinformatic analysis. Finally, a multivariate logistic regression analysis of the data showed that TOP2A, CCNB1, BIRC5, miR‑21‑5p, miR‑193b‑3p, miR‑210‑3p and miR‑31‑5p could be combined for the diagnosis of NSCLC. In conclusion, TOP2A, CCNB1, BIRC5, miR‑21‑5p, miR‑193b‑3p, miR‑210‑3p and miR‑31‑5p may therefore serve as important biomarkers and diagnostic targets for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.